Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Completes $54 Million in Private Financing

NEW YORK, Jan 8 – Structural genomics company Syrrx expects to close a $54 million Series C round of venture funding Tuesday, the company announced Monday.

This financing effort follows an October 3 announcement that Syrrx had raised $20 million in Series B venture funding. The San Diego-based company has raised $79 million to date

Lombard Odier & Cie led this private placement, which included Bay City Capital, Chemicals and Materials Enterprise Associates (CMEA), CIBC, Cooper Hill, Invesco Global Health Science Fund, Jaspers, Joe Lewis, MPM Asset Management, Versant Ventures, Wanger Asset Management and Alex Zaffaroni.

Syrrx has developed an automated “factory approach” to determine structures of proteins, in collaboration with the Genomics Institute. The company uses this technology to enhance drug discovery efforts.

" This round of financing will enable Syrrx to deepen its commitment to industrializing protein structure determination with breakthrough technologies and add important competencies that will enable us to forward integrate to become a drug discovery company," Syrrx CEO Wendell Wierenga said in a statement.

Syrrx, which has 50 employees, recently began construction of an 84,000-square-foot facility, which it will occupy in January 2002.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.